-
Ouabain (B2270) for Reliable Cell Assays
2026-09-20
This scenario-driven guide explains how Ouabain (SKU B2270) can improve the design and interpretation of Na⁺/K⁺-ATPase inhibition assays, cell viability studies, and cardiovascular research workflows. It connects mechanism, dose selection, vendor evaluation, and translational limitations to practical laboratory decisions.
-
AMD-070 Hydrochloride: CXCR4 Assay Workflows
2026-09-19
Build more informative migration, signaling, and combination assays with AMD-070 hydrochloride, a selective small-molecule CXCR4 antagonist. This workflow connects CXCR4 genotype, CXCL12-dependent phenotypes, and translational assay controls while clearly separating research observations from clinical interpretation.
-
AMPK–JAK2/STAT3 Signaling in Obesity-Related Asthma
2026-09-18
The reference study identifies reduced AMPK activity and M1 macrophage polarization as linked features of obesity-related asthma, and connects this inflammatory phenotype to JAK2/STAT3 signaling. Its combined mouse and RAW264.7-cell design supports AMPK as a mechanistic regulator of airway inflammation while also highlighting the need for careful validation beyond experimental models.
-
GS-441524 Applied Research Workflows
2026-09-18
Build more informative antiviral assays by separating GS-441524 exposure, prodrug conversion, and intracellular activation. This practical guide combines solvent handling, LC–MS/MS sampling, pharmacokinetic study design, and troubleshooting for reproducible SARS-CoV-2 research.
-
AICAR Assay Workflows and Reliability
2026-09-17
A practical, scenario-based guide to using AICAR (5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside), SKU A8184, in viability, proliferation, cytotoxicity, metabolism, and inflammation experiments. It connects formulation data, pathway controls, handling parameters, and literature-based interpretation to improve reproducibility without confusing metabolic effects with cell loss.
-
Paroxetine in Colon Cancer: MET and ERBB3
2026-09-16
The reference study identified paroxetine, a Selective serotonin reuptake inhibitor, as a repurposing candidate for colorectal cancer and linked its activity to MET and ERBB3 signaling. Across HCT116 and HT-29 models, paroxetine reduced viability, clonogenic growth, and spheroid formation, increased apoptosis, and suppressed HT-29 xenograft growth, while pathway experiments implicated AKT, ERK, p38, JNK, and caspase-3.
-
Triiodothyronine (T3) for Adipocyte Assays
2026-09-16
Use Triiodothyronine (T3) as a controlled endocrine input for adipocyte differentiation, thermogenesis, and cellular metabolism assays. This workflow separates thyroid hormone receptor activation from SEMA3E–β-catenin signaling, helping researchers build more interpretable metabolic disorder models.
-
3-Deazaneplanocin (DZNep) Workflow Guide
2026-09-15
3-Deazaneplanocin (DZNep) links S-adenosylhomocysteine hydrolase inhibition with EZH2-associated epigenetic remodeling, making it useful for mechanism-led cancer and metabolic disease assays. This guide translates that activity into practical workflows for apoptosis induction in AML cells, cancer stem cell targeting, and hepatocellular carcinoma research, with built-in controls and troubleshooting steps.
-
GKT137831: A Redox-to-Ferroptosis Assay Framework
2026-09-15
GKT137831, a dual NADPH oxidase Nox1/Nox4 inhibitor, offers a rigorous way to connect ROS generation with plasma-membrane failure. This article translates recent ferroptosis findings into practical assay design for vascular, fibrotic, and oxidative-stress research.
-
Tetrazolium Red: From Viability Signal to Translation
2026-09-14
Tetrazolium (chloride), also known as Tetrazolium Red or TTC, is more than a colorimetric reagent: it is a functional bridge between mitochondrial redox activity, tissue viability, and translational decision-making. This article places TTC staining in the mechanistic context of oxidative injury and cardamomin-mediated protection in cerebral ischemia, while outlining practical strategies for producing more decision-ready data.
-
CUX2 Neuron Loss from DNA Damage in Neuroinflammation
2026-09-14
The reference study identifies accumulated DNA damage and inadequate double-strand break repair as drivers of selective CUX2-positive layer 2/3 excitatory neuron loss during neuroinflammation. By integrating human multiple sclerosis tissue, mouse models, genetic analyses, and interferon-γ exposure, it connects neuronal subtype vulnerability to CUX2, ATF4, reactive oxygen species, and DNA repair capacity.
-
EdU Flow Cytometry Assay Kits (Cy5) Workflow
2026-09-13
EdU Flow Cytometry Assay Kits (Cy5) provide a denaturation-free way to quantify DNA synthesis during S phase using EdU incorporation and Cy5 click-chemistry detection. They are intended for research flow cytometry workflows, including proliferation, genotoxicity, and pharmacodynamic studies, rather than clinical diagnostics, in vivo labeling, or tissue imaging.
-
GS-441524: A Matrix-Aware Assay Strategy
2026-09-12
GS-441524 research is most informative when parent compound, prodrug, and active metabolite are measured as distinct analytical entities. This matrix-aware guide translates recent LC–MS/MS findings into practical decisions for antiviral assays and pharmacokinetic studies.
-
GS-441524: From Nucleoside to Translational Strategy
2026-09-11
GS-441524 is more than a single antiviral test article: it is a platform for studying nucleoside activation, prodrug conversion, matrix-specific exposure, and translational pharmacokinetics. New LC–MS/MS findings on the NGP-1 GS-441524 prodrug show why researchers should measure parent and metabolite together rather than infer biological performance from nominal dosing alone.
-
ARCA EGFP mRNA (5-moUTP): Assay Design
2026-09-11
ARCA EGFP mRNA (5-moUTP) enables direct, fluorescence-based assessment of mRNA transfection in mammalian cells. This guide goes beyond product features to explain how cap orientation, nucleotide modification, storage control, and assay architecture shape the reliability of EGFP readouts.